Respiratory disease Archives

Best in Biotech 27 Feb 2025

Eight respiratory disease companies advancing innovative therapies in 2025

Discover eight respiratory disease companies advancing their novel therapies through clinical trials in 2025.

February 27, 2025 - 12 minutesmins - By Willow Shah-Neville

News and Trends 24 Feb 2025

Over $3 billion in a month: Why is Eli Lilly starting 2025 on a buying spree?

This year has seen Eli Lilly sign several licensing deals to bolster its position across a range of therapeutic areas amid growing drug revenues.

February 24, 2025 - 7 minutesmins - By Roohi Mariam Peter

In Depth 4 Dec 2024

Idiopathic pulmonary fibrosis: Refoxy, Boehringer, Insilico, and more on the hunt for curative treatments

There is a lot of research going on in the therapeutic field of idiopathic pulmonary fibrosis, in the hope that more treatments reach patients sooner.

December 4, 2024 - 8 minutesmins - By Roohi Mariam Peter

Best in Biotech 7 Nov 2024

Cystic fibrosis: Five biotechs breathing life into the therapeutic space

In this article, we take a look at five biotechs developing potentially transformative medicines to treat this genetic disease.

November 7, 2024 - 8 minutesmins - By Roohi Mariam Peter

With its molecular clamp technology and its lead multivalent vaccine candidate targeting both RSV and hMPV, Vicebio aims to solve unmet medical needs.

News and Trends 23 Sep 2024

Vicebio and its molecular clamp vaccine raise big to tackle respiratory viruses

Discover Vicebio’s molecular clamp technology as it completes a $100 million series B round for its bivalent vaccine against RSV and hMPV.

September 23, 2024 - 9 minutesmins - By Jules Adam

News and Trends 21 Dec 2023

The big pharma race against deadly RSV steps up in 2023

GSK and Pfizer received FDA approval for their RSV vaccines in 2023. Now, AstraZeneca has joined the race with its latest acquisition.

December 21, 2023 - 7 minutesmins - By Roohi Mariam Peter

News and Trends 11 Jul 2023

Inhaled mRNA medicines redefine respiratory disease treatment

By Carsten Rudolph, co-founder and CEO of Ethris Advancements in mRNA technology have led to the development of inhaled mRNA medicines, which hold tremendous potential for revolutionizing the treatment of respiratory diseases, an area with high unmet needs. However, the primary hurdle in its clinical application lies in the identification of a delivery system that […]

July 11, 2023 - 3 minutesmins - By External Contributor

News and Trends 8 Mar 2023

Affibody and Chiesi Group to develop treatments for respiratory diseases

Affibody AB and Chiesi Farmaceutici S.p.A have announced a collaboration and licensing agreement to develop and commercialize innovative treatments for respiratory diseases using Affibody’s proprietary technology. Under the terms of the agreement, the parties will collaborate to progress up to three programs based on Affibody molecules against undisclosed targets for respiratory diseases. Chiesi will fund […]

March 8, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 17 Feb 2023

Positive results for INOVIO recurrent respiratory papillomatosis trial

INOVIO Pharmaceuticals has announced positive preliminary results from the second cohort of its phase 1/2 clinical trial evaluating INO-3107 for the treatment of HPV 6 and HPV 11-associated recurrent respiratory papillomatosis (RRP) in adults. In the second cohort of 11 patients who were administered INO-3107 via the exploratory side port needle, 10 of the 11 […]

February 17, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 21 Dec 2022

Poolbeg identifies new potential drug candidates for RSV infections

Poolbeg Pharma says it has successfully identified potential new drug candidates from its respiratory syncytial virus (RSV) artificial intelligence (AI) program with OneThree Biotech, Inc. Since initiating the collaboration in February 2022, Poolbeg’s scientific team has worked with OneThree to build a tailored AI approach that leverages Poolbeg’s RSV human challenge trial data to identify […]

December 21, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 19 Dec 2022

Watch: Atriva Therapeutics at BIO-Europe

Atriva Therapeutics’ mission is to develop an antiviral therapy platform against severe respiratory and systemic diseases with a high unmet medical need induced by RNA viruses, e.g., influenza and COVID-19. The clinical-stage biopharmaceutical company is pioneering the development of host-targeting antiviral therapies, making development of viral resistance unlikely, and thereby significantly contributing to pandemic preparedness. […]

December 19, 2022 - 1 minutemin - By Jim Cornall

News and Trends 6 Dec 2022

Tetra announce significant results from the study of Onternabez combined with Favipiravir

Tetra Bio-Pharma Inc. a leader in cannabinoid-derived drug discovery and development announced today significant results from the study of Onternabez combined with Favipiravir. The combination acts against ARDS (acute respiratory distress syndrome), Sepsis, and Covid-19 through PREPAiRE, an artificial intelligence (AI) powered platform. The platform, the companies say, purposely integrates target identification, validation, lead discovery […]

December 6, 2022 - 2 minutesmins - By Liza Laws

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Respiratory disease

Eight respiratory disease companies advancing innovative therapies in 2025

Over $3 billion in a month: Why is Eli Lilly starting 2025 on a buying spree?

Idiopathic pulmonary fibrosis: Refoxy, Boehringer, Insilico, and more on the hunt for curative treatments

Cystic fibrosis: Five biotechs breathing life into the therapeutic space

Vicebio and its molecular clamp vaccine raise big to tackle respiratory viruses

The big pharma race against deadly RSV steps up in 2023

Inhaled mRNA medicines redefine respiratory disease treatment

Affibody and Chiesi Group to develop treatments for respiratory diseases

Positive results for INOVIO recurrent respiratory papillomatosis trial

Poolbeg identifies new potential drug candidates for RSV infections

Watch: Atriva Therapeutics at BIO-Europe

Tetra announce significant results from the study of Onternabez combined with Favipiravir

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!